Neulasta and Breathing - slowed or stopped - a phase IV clinical study of FDA data

Summary:

Breathing - slowed or stopped is reported as a side effect among people who take Neulasta (pegfilgrastim), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Taxotere, and have Lymphoma.

The phase IV clinical study analyzes which people have Breathing - slowed or stopped when taking Neulasta. It is created by eHealthMe based on reports of 92,148 people who have side effects when taking Neulasta from the FDA, and is updated regularly.

What is Neulasta?

Neulasta has active ingredients of pegfilgrastim. It is often used in agranulocytosis. eHealthMe is studying from 92,286 Neulasta users. Check the latest studies of Neulasta.

What is Breathing - slowed or stopped?

Breathing - slowed or stopped is found to be associated with 1,222 drugs and 2,169 conditions by eHealthMe. Check the latest studies of Breathing - slowed or stopped.

On Jul, 16, 2026

92,148 people reported to have side effects when taking Neulasta.
Among them, 12 people (0.01%) have Breathing - slowed or stopped.

Could Neulasta cause Breathing - slowed or stopped?

Among these 12 people:

How long have people been on Neulasta when they have Breathing - slowed or stopped? *

What is the gender of people who have Breathing - slowed or stopped when taking Neulasta? *

female: 83.33 %
male: 16.67 %

What is the age of people who have Breathing - slowed or stopped when taking Neulasta? *

What are other drugs people take besides Neulasta? *

Taxotere: 5 people, 41.67%
Cyclophosphamide: 4 people, 33.33%
Doxorubicin Hydrochloride: 3 people, 25.00%
Humalog: 2 people, 16.67%
Lactulose: 2 people, 16.67%
Lantus: 2 people, 16.67%
Decadron: 2 people, 16.67%
Ms Contin: 2 people, 16.67%
Nexium: 2 people, 16.67%
Carboplatin: 2 people, 16.67%

What are other side effects people have besides Breathing - slowed or stopped? *

White Blood Cell Count Decreased: 6 people, 50.00%
Thrombocytopenia (decrease of platelets in blood): 6 people, 50.00%
Haemoglobin Decreased: 5 people, 41.67%
Haematocrit Decreased: 5 people, 41.67%
Diarrhea: 4 people, 33.33%
Pulse Absent: 4 people, 33.33%
Acute Kidney Failure: 4 people, 33.33%
Respiratory Acidosis (respiratory failure or ventilatory failure, causes the ph of blood and other bodily fluids to decrease): 3 people, 25.00%
Septic Shock (shock due to blood infection): 3 people, 25.00%
Ards (Acute Respiratory Distress Syndrome) (sudden failure of the respiratory (breathing) system): 3 people, 25.00%

What are the existing conditions these people have? *

Lymphoma (cancer that begins in immune system cells): 2 people, 16.67%
Type 2 Diabetes: 1 person, 8.33%
Prostate Cancer Metastatic: 1 person, 8.33%
Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 1 person, 8.33%
High Blood Pressure: 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Neulasta and have Breathing - slowed or stopped?

- Check whether Breathing - slowed or stopped is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Neulasta:

Neulasta (92,286 reports)

Browse all side effects of Neulasta:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Breathing - slowed or stopped:

Breathing - slowed or stopped (1,222 drugs)

Browse all the conditions that are associated with Breathing - slowed or stopped:

Breathing - slowed or stopped (2,169 conditions)

Related publications that referenced our studies

Khan A, Yasin Z, "Hyperleukocytosis Caused By Neulasta Complicated By Leukostasis Versus Asymptomatic Uncomplicated Hyperleukocytosis In AML. Two Cases and When To Leukapherese.", Am Soc Hematology, 2017 Jan .
Khan A, Yasin Z, "Hyperleukocytosis Caused By Neulasta Complicated By Leukostasis Versus Asymptomatic Uncomplicated Hyperleukocytosis In AML. Two Cases and When To Leukapherese.", Am Soc Hematology, 2017 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on pegfilgrastim (the active ingredients of Neulasta) and Neulasta (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.